Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan 14;20(2):401-13.
doi: 10.3748/wjg.v20.i2.401.

Then and now: the progress in hepatitis B treatment over the past 20 years

Dina Halegoua-De Marzio  1 , Hie-Won Hann  1
Affiliations
Review

Then and now: the progress in hepatitis B treatment over the past 20 years

Dina Halegoua-De Marzio et al. World J Gastroenterol. .

Abstract

The ultimate goals of treating chronic hepatitis B (CHB) is prevention of hepatocellular carcinoma (HCC) and hepatic decompensation. Since the advent of effective antiviral drugs that appeared during the past two decades, considerable advances have been made not only in controlling hepatitis B virus (HBV) infection, but also in preventing and reducing the incidence of liver cirrhosis and HCC. Furthermore, several recent studies have suggested the possibility of reducing the incidence of recurrent or new HCC in patients even after they have developed HCC. Currently, six medications are available for HBV treatment including, interferon and five nucleoside/nucleotide analogues. In this review, we will examine the antiviral drugs and the progresses that have been made with antiviral treatments in the field of CHB.

Keywords: Chronic hepatitis B; Hepatocellular carcinoma; Nucleoside analogues; Nucleotide analogues; Treatment of hepatitis B.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progress in the field of hepatitis B virus. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HCC: Hepatocellular carcinoma.
Figure 2
Figure 2
Five phases of chronic hepatitis B. Adapted from Tong et al[37]. ALT: Alanine aminotransferase; Anti-HBc: Hepatitis B core antibody; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; Anti-HBe: Hepatitis B e antibody.
Figure 3
Figure 3
Timeline of approved therapies for chronic hepatitis B. IFN: Interferon.
Figure 4
Figure 4
Characteristics of approved drugs for treatment of hepatitis B.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129. - PubMed
    1. Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;191:541–546. - PubMed
    1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745. - PubMed
    1. Blumberg BS. Australia antigen and the biology of hepatitis B. Science. 1977;197:17–25. - PubMed
    1. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970;1:695–698. - PubMed

MeSH terms

Substances